Zydus Cadila gets USFDA nod for antidepressant drug
Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Nortriptyline Hydrochloride capsules USP, in strengths of 10 mg, 25 mg, 50 mg and 75 mg, Cadila Healthcare said in a regulatory filing.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Food and Drug Administration (FDA) | Nortriptyline | Pharmaceuticals | USA Health